Don't miss this informative webinar!
This week's FierceBiotech is brought to you by Camargo.
Trouble viewing? Click here. |
Date: Tuesday, July 16, 2019 Time: 11am ET / 8am PT Duration: 1 Hour |
|
| You've identified your product as a candidate for approval via the 505(b)(2) pathway and completed a successful pre-IND meeting. What comes next?
In part two of this webinar series on the 505(b)(2) pathway, Ken delves deeper into IND-enabling activities including CMC, toxicology and PK/PD. Discover tips for harnessing creativity to reference the right data, design and conduct the right studies and get your program to the clinic faster. Save Your Seat |
|
|
Want to reach 137,000+ FierceBiotech subscribers with your own message?
Contact aalcover@fiercemarkets.com or call 202-824-5074.
About this email: In order to receive FierceBiotech for free, we ask that you accept an occasional email promotion from our sponsors. We carefully screen each promotion and never sell or give away your personal information. If you do not want to receive these messages, you can unsubscribe entirely from FierceBiotech.
Click here to unsubscribe. Refer to our Privacy Policy.
FierceMarkets, a division of Questex, LLC
1900 L St. NW Suite 400
Washington, DC 20036 |
|
|
